<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

First Stable, Serially Transplantable M5 AML PDX Model Published

It is traditionally difficult to develop stable blood cancer patient-derived xenograft (PDX) models. Historically, commercially available models have been transient and non-transferable through passages. This only allows one-shot studies providing a gross measure of response, not suitable for efficacy studies.

A recent publication has now detailed the first stable serially transplantable PDX of M5 acute myeloid leukemia in mice, and looked at the differing responses to anti-leukemia drug activity, including chemotherapy and a newer targeted agent.

M5 AML Patient, with Confirmed Diagnosis and Common AML Features

The foundation of the paper is the development of the PDX model, from a patient with M5 subtype AML. The patient’s bone marrow cells were positive for typical myeloid surface markers CD45, CD33, CD123, and CD13, and negative for nonmyeloid markers, for example, CD19 and CD3. Sequencing/mutation analysis also confirmed many features often seen in AML including heterozygous FLT3-ITD, along with IDH2-R140Q, DNMT3A-R882H, and NPM1.

Mononuclear cells isolated from the sample were engrafted into five irradiated NOD/SCID mice, and monitored weekly for the peripheral appearance of leukemic cells (CD45+), which appeared after a 5 month latency period with typical AML symptoms. The engraftment had a high take rate, and particularly high levels of engraftment.

Stable, Transplantable PDX Model Developed, Recapitulating Patient Disease

Leukemic cells from this P0 model were then serially passaged with a 100% take rate, with re-engraftments showing robust growth and 100% mortality, creating a robust and stable AML model.

Flow cytometry analysis of the PDX model revealed markers identical to the patient (CD45+, CD33+, CD13+, CD123+, CD38+, and CD19-, CD34-, HLA-DR-) and genotyping of the model confirmed the heterozygous IDH2 R140Q mutation, FLT3-ITD, DNMT3A R882H, and NPM1, as seen for the patient.

These results confirmed the presence of stable AML in the mice without phenotypic and genotypic shift, and provided the first AML model with both FLT3-ITD and IDH2 mutations.

Model Robust Growth Likely Supported by a GM-CSF and IL-3 Autocrine Mechanism

GM-CSF and IL-3 are the two key cytokines required for myeloid lineage cell growth and differentiation, and they are also important for the growth of some AML cells. Murine GM-CSF and IL-3 don’t recognize their human counterpart receptors, so can’t promote human PDX growth.

High levels of human GM-CSF and IL-3 were found in the blood of the mice implanted with the PDX, produced by leukemic cells, suggesting that an autocrine mechanism involving these factors could be responsible for the robust growth of the model (which has been published on previously).

Chemotherapy vs Targeted Therapy Efficacy Studies

The stable PDX provides the perfect model for efficacy studies, and the paper went on to compare current standard of care (SoC) treatment with a possible future targeted AML therapy, aiming to provide useful information for the clinical application of these drugs:

Treatment options for AML remained static for many years, with new progress only being seen this year with agents approved which target FLT3 mutation as well as IDH2 mutation. Further targeted agents such as AC220 are needed to help treat this complex disease.

Current SoC Induces Temporary Remission in Peripheral Blood

Treatment with AraC initially went well – treatment of the model almost completely suppressed leukemia in the peripheral blood, and to a lesser extent other organs. Disease symptoms were reduced, and lifetime extended.

However, treatment withdrawal caused a rapid relapse in peripheral blood within days, with clinical symptoms returning and eventual mortality. Continuous dosing was also trialed, which did delay disease onset but could still not prevent eventual death.

FLT3 Targeted Agent Suggested a “Possible Cure”

In comparison, treatment with AC220 produced stellar results. The drug caused complete remission – suppressing leukemia in peripheral blood, as well as in bone and spleen, as far as 130 days post-inoculation. This translated into a reduction in symptoms and an extension of life.

There was also no relapse of symptoms after high dose treatment withdrawal, and no clinical signs of disease until the end of the study. Leukemia was not detected in a range of organs and gross pathology examination during autopsy, suggesting the possibility of a “cure”.

AC220 and AML PDX Model Validated in AML Treatment Research

This study seemed to reveal an important limitation of standard induction chemotherapy – with only a temporary/incomplete suppression of AML in an M5 FLT3-ITD PDX. This disease relapse is somewhat reflective of the clinical situation, and demonstrates why new treatment options are needed.

The study also confirms that FLT3-ITD plays a critical role in at least maintaining AML in this model – acting as an oncogenic driver, and that AC220 could play an important role in the future treating patients with this mutation.


Related Posts